Michele Simonato

Involvement of the neuropeptide nociceptin/orphanin FQ in kainate seizures.

Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist.

Pro-nociceptin/orphanin FQ and NOP receptor mRNA levels in the forebrain of food deprived rats.

Changes in NPY-mediated modulation of hippocampal [3H]D-aspartate outflow in the kindling model of epilepsy.

Delayed epileptogenesis in nociceptin/orphanin FQ-deficient mice.

Mechanisms of action of CHF3381 in the forebrain.

On the role of somatostatin in seizure control: clues from the hippocampus.

Kainate seizures increase nociceptin/orphanin FQ release in the rat hippocampus and thalamus: a microdialysis study.

Alterations in seizure susceptibility and in seizure-induced plasticity after pharmacologic and genetic manipulation of the fibroblast growth factor-2 system.

BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes.

Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.

Angels and demons: neurotrophic factors and epilepsy.

Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin-releasing factor (CRF) in the rat brain: evidence for involvement of the bed nucleus of the stria terminalis.

Adenosine receptor antagonists alter the stability of human epileptic GABAA receptors.

Fgf-2 overexpression increases excitability and seizure susceptibility but decreases seizure-induced cell loss.

Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model.

The biocompatibility of materials used in printed circuit board technologies with respect to primary neuronal and K562 cells.

Enhancement of GABA(A)-current run-down in the hippocampus occurs at the first spontaneous seizure in a model of temporal lobe epilepsy.

Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease.

Are the neurotrophic factors a suitable therapeutic target for the prevention of epileptogenesis?

Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures.

Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus.

Identification of new epilepsy treatments: issues in preclinical methodology.

Bystander effect on brain tissue of mesoangioblasts producing neurotrophins.

Loss of cortical GABA terminals in Unverricht-Lundborg disease.

Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design.

Finding a better drug for epilepsy: antiepileptogenesis targets.

Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.

Issues for new antiepilepsy drug development.

Increased excitability in tat-transgenic mice: role of tat in HIV-related neurological disorders.

Progress in gene therapy for neurological disorders.

Bradykinin B₂ receptors increase hippocampal excitability and susceptibility to seizures in mice.

Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy.

Proposal for a "phase II" multicenter trial model for preclinical new antiepilepsy therapy development.

Implication of fibroblast growth factors in epileptogenesis-associated circuit rearrangements.

Gene therapy for epilepsy.

Impairment of GABA release in the hippocampus at the time of the first spontaneous seizure in the pilocarpine model of temporal lobe epilepsy.

The challenge and promise of anti-epileptic therapy development in animal models.

Identification of miRNAs differentially expressed in human epilepsy with or without granule cell pathology.

Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network in human epileptic hippocampus.

Increased extracellular levels of glutamate in the hippocampus of chronically epileptic rats.

Opportunities for improving animal welfare in rodent models of epilepsy and seizures.

MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy--comparison with human epileptic samples.

Silencing Status Epilepticus-Induced BDNF Expression with Herpes Simplex Virus Type-1 Based Amplicon Vectors.

Advances in the development of biomarkers for epilepsy.

Common data elements and data management: Remedy to cure underpowered preclinical studies.

WONOEP appraisal: Development of epilepsy biomarkers-What we can learn from our patients?

Effects of [Nphe1, Arg14, Lys15] N/OFQ-NH2 (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress.

Engineered HSV vector achieves safe long-term transgene expression in the central nervous system.

Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes.

eIF4B phosphorylation at Ser504 links synaptic activity with protein translation in physiology and pathology.

Standardization procedure for plasma biomarker analysis in rat models of epileptogenesis: Focus on circulating microRNAs.

Identification and characterization of outcome measures reported in animal models of epilepsy: Protocol for a systematic review of the literature-A TASK2 report of the AES/ILAE Translational Task Force of the ILAE.

Harmonization in preclinical epilepsy research: A joint AES/ILAE translational initiative.

Meta-Analysis of MicroRNAs Dysregulated in the Hippocampal Dentate Gyrus of Animal Models of Epilepsy.

Seizure-Suppressant and Neuroprotective Effects of Encapsulated BDNF-Producing Cells in a Rat Model of Temporal Lobe Epilepsy.

New Tools for Epilepsy Therapy.

Corrigendum: New Tools for Epilepsy Therapy.